Nephron Clinical Practice
Original Paper
Association of Insulin Resistance with de novo Coronary Stenosis after Percutaneous Coronary Artery Intervention in Hemodialysis PatientsNishimura M.a · Tokoro T.b · Nishida M.c · Hashimoto T.c · Kobayashi H.c · Yamazaki S.c · Imai R.d · Okino K.e · Takahashi H.f · Ono T.caCardiovascular Division, Divisions of bNephrology, cUrology, dOrthopedics and eSurgery, Toujinkai Hospital, Kyoto, and fDepartment of Clinical Sciences and Laboratory Medicine, Kansai Medical University, Osaka, Japan
|
|
Nephron Clin Pract 2008;109:c9
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Subscribe
For eJournal Archive and eJournal Backfiles information please contact Karger service
* The final prices may differ from the prices shown due to specifics of VAT rules.
Article / Publication Details
First-Page Preview
Received: September 18, 2007
Accepted: January 21, 2008
Published online: May 16, 2008
Issue release date: June 2008
Number of Print Pages: 1
Number of Figures: 0
Number of Tables: 5
eISSN: 1660-2110 (Online)
For additional information: https://www.karger.com/NEC
Abstract
Background/Aims: De novo coronary atherosclerosis may be involved in the poor prognosis after percutaneous coronary artery intervention (PCI) in hemodialysis patients. We aimed to clarify the factors associated with de novocoronary lesion in this population. Methods: We enrolled 106 patients on hemodialysis (72 men, 34 women; mean age, 65.4 ± 8.9 years), who had firstly received PCI with bare-metal stents for single coronary lesions and undergone follow-up coronary angiography (CAG) 6 months thereafter. Coronary lesion with stenosis of >50% diameter that was newly recognized at follow-up CAG was defined as de novo coronary stenosis. The values of biochemical parameters were determined as the means of several measurements between PCI and follow-up CAG. Results: Follow-up CAG revealed de novo coronary stenosis in 40 (37.7%) of the 106 hemodialysis patients who had received PCI. Stepwise multiple logistic regression analysis showed that de novo coronary lesions were strongly associated with homeostasis model assessment insulin resistance index (HOMA-IR; 1 mM× [µU/ml]: odds ratio, 7.312; p =0.001). This significant association of HOMA-IR with de novo coronary stenosis was recognized in the diabetic and nondiabetic subgroups. Conclusions: Insulin resistance may be involved in the progression of nonculprit coronary atherosclerosis after PCI in hemodialysis patients.
© 2008 S. Karger AG, Basel
Related Articles:
References
- Le Feuvre C, Dambrin G, Helft G, Beygui F, Touam M, Grünfeld JP, Vacheron A, Metzger JP: Clinical outcome following coronary angioplasty in dialysis patients: a case-control study in the era of coronary stenting. Heart 2001;85:556–560.
- Yasuda K, Kasuga H, Aoyama T, Takahashi H, Toriyama T, Kawade Y, Iwashima S, Yamada S, Kawahara H, Maruyama S, Yuzawa Y, Ishii H, Murohara T, Matsuo S: Comparison of percutaneous coronary intervention with medication in the treatment of coronary artery disease in hemodialysis patients. J Am Soc Nephrol 2006;17:2322–2332.
- Hemmelgarn BR, Southern D, Culleton BF, Mitchell LB, Knudtson ML, Ghali WA, for the Alberta Provincial Project for Outcomes Assessment in Coronary Heart Disease (APPROACH) Investigators: Survival after coronary revascularization among patients with kidney disease. Circulation 2004;110:1890–1895.
- Zouridakis E, Avanzas P, Arrovo-Espliguero R, Fredericks S, Kaski JC: Markers of inflammation and rapid coronary artery disease progression in patients with stable angina pectoris. Circulation 2004;110:1747–1753.
-
Glaser R, Selzer F, Faxon DP, Laskey WK, Cohen HA, Slater J, Detre KM, Wilensky RL: Clinical progression of incidental, asymptomatic lesions discovered during culprit vessel coronary intervention. Circulation 205;111:143–149.
- Devereux RB, Koren MJ, de Simone G, Okin PM, Kligfield P: Methods for detection of left ventricular hypertrophy: application to hypertensive heart disease. Eur Heart J 1993;14(suppl D):8–15.
- Stack AG, Bloembergen WE: Prevalence and clinical correlates of coronary artery disease among new dialysis patients in the United States: a cross-sectional study. J Am Soc Nephrol 2001;12:1516–1523.
- Mark RH: Impact of end-stage renal disease and dialysis on glycemic control. Semin Dial 2000;13:4–8.
- Shinozaki K, Kashiwagi A, Nishio Y, Okamura T, Yoshida Y, Masada M, Toda N, Kikkawa R: Abnormal biopterin metabolism is a major cause of impaired endothelium-dependent relaxation through nitric oxide/O2 imbalance in insulin-resistant rat aorta. Diabetes 1999;48:2437–2445.
- Shinozaki K, Hirayama A, Nishio Y, Yoshida Y, Ohtani T, Okamura T, Masada M, Kikkawa R, Kodama K, Kashiwagi A: Coronary endothelial dysfunction in the insulin-resistant state is linked to abnormal pteridine metabolism and vascular oxidative stress. J Am Coll Cardiol 2001;38:1821–1828.
- Navarro-Cid J, Maeso R, Perez-Vizcaino F, Cachofeiro V, Ruilope LM, Tamargo J, Lahera V: Effects of losartan on blood pressure, metabolic alterations, and vascular reactivity in the fructose-induced hypertensive rat. Hypertension 1995;26:1074–1078.
- Shinozaki K, Ayajiki K, Nishio Y, Sugaya T, Kashiwagi A, Okamura T: Evidence for a causal role of the renin-angiotensin system in vascular dysfunction associated with insulin resistance. Hypertension 2004;43:255–262.
- Kaysen GA, Dubin JA, Muller HG, Mitch WE, Rosales LM, Levin NW: Relationships among inflammation, nutrition, and physiologic mechanisms establishing albumin levels in hemodialysis patients. Kidney Int 2002;61:2240–2249.
- Kalantar-Zadeh K, Kopple JD: Relative contributions of nutrition and inflammation to clinical outcome in dialysis patients. Am J Kidney Dis 2001;38:1343–1350.
- Flores EA, Bistrian BR, Pomposelli JJ, Dinarello CA, Blackburn GL, Istfan NW: Infusion of tumor necrosis factor/cachectin promotes muscle catabolism in the rat. A synergistic effect with interleukin 1. J Clin Invest 1989;83:1614–1622.
- Means RT Jr, Krantz SB: Progress in understanding the pathogenesis of the anemia of chronic disease. Blood 1992;80:1639–1647.
- Means RT Jr, Krantz SB: Inhibition of human erythroid colony-forming units by tumor necrosis factor requires beta interferon. J Clin Invest 1993;91:416–419.
- Means RT Jr, Krantz SB, Luna J, Marsters SA, Ashkenazi A: Inhibition of murine erythroid colony function in vitro by interferon gamma and correction by interferon receptor immunoadhesin. Blood 1994;83:911–915.
- Voulgari PV, Kolios G, Papadopoulos GK, Katsaraki A, Seferiadis K, Drosos AA: Role of cytokines in the pathogenesis of anemia of chronic disease in rheumatoid arthritis. Clin Immunol 1999;92:153–160.
- Borissova AM, Djambazova A, Todorov K, Dakovska L, Tankova T, Kirilov G: Effect of erythropoietin on the metabolic state and peripheral insulin sensitivity in diabetic patients on hemodialysis. Nephrol Dial Transplant 1993;8:93.
- Mak RH: Effect of recombinant human erythropoietin on insulin, amino acid, and lipid metabolism in uremia. J Pediatr 1996;129:97–104.
- Mak RH: Intravenous 1,25 dihydroxycholecalciferol corrects glucose intolerance in hemodialysis patients. Kidney Int 1992;41:1049–1054.
- Kautzky-Willer A, Pacini G, Barnas U, Ludvik B, Streli C, Graf H, Prager R: Intravenous calcitriol normalizes insulin sensitivity in uremic patients. Kidney Int 1995;47:200–206.
- Lin S, Lin Y, Lu K, Diang LK, Chyr SH, Liao WK, Shieh SD: Effects of intravenous calcitriol on lipid profiles and glucose tolerance in uraemic patients with secondary hyperparathyroidism. Clin Sci 1994;87:533–538.
- Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R: Survival of patients undergoing hemodialysis with paricalcitol or carlcitriol therapy. N Engl J Med 2003;349:446–456.
- Shoji T, Shinohara K, Kimoto E, Emoto M, Tahara H, Koyama H, Inaba M, Fukumoto S, Ishimura E, Miki T, Tabata T, Nishizawa Y: Lower risk for cardiovascular mortality in oral 1 alpha-hydroxy vitamin D3 users in a haemodialysis population. Nephrol Dial Transplant 2004;19:179–184.
- Goldsmith DJ, Covic A, Sambrook PA, Ackrill P: Vascular calcification in long-term haemodialysis patients in a single unit: a retrospective analysis. Nephron 1997;77:37–43.
- Milliner DS, Zimsmeister AR, Lieberman E, Landing B: Soft tissue calcification in pediatric patients with end-stage renal disease. Kidney Int 1990;38:931–936.
- Matsuda M, DeFronzo RA: Insulin sensitivity indices obtained from oral glucose tolerance testing. Comparison with the euglycemic insulin clamp. Diabetes Care 1999;22:1462–1470.
- Ferrannini E, Mari A: How to measure insulin sensitivity. J Hypertens 1998;16:895–906.
- Matthews DR, Hosker JP, Rudenski AS Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412–419.
- Bonora E, Targger G, Alberiche M,Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000;23:57–63.
- Emoto M, Nishizawa Y, Maekawa K, Hiura Y, Kanda H, Kawagishi T, Shoji T, Okuno Y, Morii H: Homeostasis model assessment as a clinical index of insulin resistance in type 2 diabetic patients treated with sulfonylureas. Diabetes Care 1999;22:818–822.
- Shoji T, Emoto M, Nishizawa Y. HOMA index to assess insulin resistance in renal failure patients. Nephron 2001;89:348–349.
- Katsuki A, Sumida Y, Urakawa H, Gabazza EC, Murashima S, Morioka K, Kitagawa N, Tanaka T, Araki-Sasaki R, Hori Y, Nakatani K, Yano Y, Adachi Y: Neither homeostasis model assessment nor quantitative insulin sensitivity check index can predict insulin resistance in elderly patients with poorly controlled type 2 diabetes mellitus. J Clin Endocrinol Metab 2002;87:5332–5335.
- Defronzo RA, Tobin JD, Andres R: The glucose clamp technique: a method for the quantification of beta-cell sensitivity to glucose and tissue sensitivity to insulin. Am J Physiol 1979;237:E214–E223.
Article / Publication Details
First-Page Preview
Received: September 18, 2007
Accepted: January 21, 2008
Published online: May 16, 2008
Issue release date: June 2008
Number of Print Pages: 1
Number of Figures: 0
Number of Tables: 5
eISSN: 1660-2110 (Online)
For additional information: https://www.karger.com/NEC
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
